Valuation dashboard for Soligenix, Inc. (SNGX) with P/E N/A, P/B 0.86, EV/EBITDA 0.36 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $0.36, SNGX has negative trailing earnings (P/E not meaningful) and an ROE of -181.02%. Market capitalisation stands at $5M.
Balance sheet quality for SNGX: current ratio of 2.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.86 |
| EV / EBITDA | 0.36 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| SNGX | Soligenix, Inc. | $5M | 0.86 | -181.0% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $0.36 |
| Market Cap | $5M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -181.02% |
| Return on Invested Capital | -151.39% |
| Return on Assets | -97.52% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CANF · CMND · ENSC · KZIA · OGEN · QLGN · SILO
Explore sector: Healthcare · Biotechnology
More sections of SNGX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks